Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Equity Average (2021 - 2024)

Opus Genetics (IRD) has disclosed Equity Average for 7 consecutive years, with $44.0 million as the latest value for Q3 2023.

  • On a quarterly basis, Equity Average rose 232.37% to $44.0 million in Q3 2023 year-over-year; TTM through Sep 2023 was $44.0 million, a 232.37% increase, with the full-year FY2022 number at $34.2 million, changed N/A from a year prior.
  • Equity Average was $44.0 million for Q3 2023 at Opus Genetics, up from $39.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $44.0 million in Q3 2023 to a low of $13.2 million in Q3 2022.
  • A 3-year average of $25.8 million and a median of $21.4 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: crashed 38.61% in 2022, then soared 232.37% in 2023.
  • Opus Genetics' Equity Average stood at $21.4 million in 2021, then soared by 35.82% to $29.1 million in 2022, then skyrocketed by 51.4% to $44.0 million in 2023.
  • Per Business Quant, the three most recent readings for IRD's Equity Average are $44.0 million (Q3 2023), $39.5 million (Q2 2023), and $43.7 million (Q1 2023).